APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urokinase Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urokinase Injection Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchUrokinase Injection Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Urokinase Injection Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Urokinase Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urokinase Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Urokinase Injection Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Urokinase Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urokinase Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urokinase Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urokinase Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urokinase Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urokinase Injection market include NDPHARM, Microbic Biosystems Inc, Techpool, Jiangsu Aidea Pharmaceutical, Jiangxi Haoran Bio-Pharma, LIVZON and Wanhua Biochem, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urokinase Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urokinase Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urokinase Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urokinase Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Urokinase Injection Segment by Company

NDPHARM

Microbic Biosystems Inc

Techpool

Jiangsu Aidea Pharmaceutical

Jiangxi Haoran Bio-Pharma

LIVZON

Wanhua Biochem

Urokinase Injection Segment by Type

10000-100000IU

100000-1000000IU

Others

Urokinase Injection Segment by Application

Hospital

Clinic

Others

Urokinase Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Urokinase Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Urokinase Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urokinase Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Urokinase Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urokinase Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urokinase Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urokinase Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urokinase Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urokinase Injection industry.

Chapter 3: Detailed analysis of Urokinase Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Urokinase Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Urokinase Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urokinase Injection Industry Trends Table 2. Urokinase Injection Industry Drivers Table 3. Urokinase Injection Industry Opportunities and Challenges Table 4. Urokinase Injection Industry Restraints Table 5. Global Urokinase Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urokinase Injection Revenue Share by Company (2021-2026) Table 7. Global Urokinase Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Urokinase Injection Sales Volume Share by Company (2021-2026) Table 9. Global Urokinase Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Urokinase Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Urokinase Injection Key Company Manufacturing Base & Headquarters Table 12. Global Urokinase Injection Company, Product Type & Application Table 13. Global Urokinase Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Urokinase Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10000-100000IU Table 18. Significant Companies of 100000-1000000IU Table 19. Significant Companies of Others Table 20. Global Urokinase Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Urokinase Injection Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Urokinase Injection Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Urokinase Injection Sales Volume Share by Type (2021-2026) Table 24. Global Urokinase Injection Sales Volume Share by Type (2027-2032) Table 25. Global Urokinase Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Urokinase Injection Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Urokinase Injection Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Urokinase Injection Sales Value Share by Type (2021-2026) Table 29. Global Urokinase Injection Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global Urokinase Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Urokinase Injection Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Urokinase Injection Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Urokinase Injection Sales Volume Share by Application (2021-2026) Table 37. Global Urokinase Injection Sales Volume Share by Application (2027-2032) Table 38. Global Urokinase Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Urokinase Injection Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Urokinase Injection Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Urokinase Injection Sales Value Share by Application (2021-2026) Table 42. Global Urokinase Injection Sales Value Share by Application (2027-2032) Table 43. Global Urokinase Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Urokinase Injection Sales by Region (2021-2026) & (K Units) Table 45. Global Urokinase Injection Sales Market Share by Region (2021-2026) Table 46. Global Urokinase Injection Sales by Region (2027-2032) & (K Units) Table 47. Global Urokinase Injection Sales Market Share by Region (2027-2032) Table 48. Global Urokinase Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Urokinase Injection Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Urokinase Injection Sales Value Share by Region (2021-2026) Table 51. Global Urokinase Injection Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Urokinase Injection Sales Value Share by Region (2027-2032) Table 53. Global Urokinase Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Urokinase Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Urokinase Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Urokinase Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Urokinase Injection Sales by Country (2021-2026) & (K Units) Table 58. Global Urokinase Injection Sales Market Share by Country (2021-2026) Table 59. Global Urokinase Injection Sales by Country (2027-2032) & (K Units) Table 60. Global Urokinase Injection Sales Market Share by Country (2027-2032) Table 61. Global Urokinase Injection Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Urokinase Injection Sales Value Market Share by Country (2021-2026) Table 63. Global Urokinase Injection Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Urokinase Injection Sales Value Market Share by Country (2027-2032) Table 65. NDPHARM Company Information Table 66. NDPHARM Business Overview Table 67. NDPHARM Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. NDPHARM Urokinase Injection Product Portfolio Table 69. NDPHARM Recent Development Table 70. Microbic Biosystems Inc Company Information Table 71. Microbic Biosystems Inc Business Overview Table 72. Microbic Biosystems Inc Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Microbic Biosystems Inc Urokinase Injection Product Portfolio Table 74. Microbic Biosystems Inc Recent Development Table 75. Techpool Company Information Table 76. Techpool Business Overview Table 77. Techpool Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Techpool Urokinase Injection Product Portfolio Table 79. Techpool Recent Development Table 80. Jiangsu Aidea Pharmaceutical Company Information Table 81. Jiangsu Aidea Pharmaceutical Business Overview Table 82. Jiangsu Aidea Pharmaceutical Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Jiangsu Aidea Pharmaceutical Urokinase Injection Product Portfolio Table 84. Jiangsu Aidea Pharmaceutical Recent Development Table 85. Jiangxi Haoran Bio-Pharma Company Information Table 86. Jiangxi Haoran Bio-Pharma Business Overview Table 87. Jiangxi Haoran Bio-Pharma Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Jiangxi Haoran Bio-Pharma Urokinase Injection Product Portfolio Table 89. Jiangxi Haoran Bio-Pharma Recent Development Table 90. LIVZON Company Information Table 91. LIVZON Business Overview Table 92. LIVZON Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. LIVZON Urokinase Injection Product Portfolio Table 94. LIVZON Recent Development Table 95. Wanhua Biochem Company Information Table 96. Wanhua Biochem Business Overview Table 97. Wanhua Biochem Urokinase Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Wanhua Biochem Urokinase Injection Product Portfolio Table 99. Wanhua Biochem Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Urokinase Injection Distributors List Table 103. Urokinase Injection Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Urokinase Injection Product Image Figure 2. Global Urokinase Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urokinase Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Urokinase Injection Sales (2021-2032) & (K Units) Figure 5. Global Urokinase Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Urokinase Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10000-100000IU Image Figure 10. 100000-1000000IU Image Figure 11. Others Image Figure 12. Global Urokinase Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Urokinase Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Urokinase Injection Sales Volume Share by Type (2021-2032) Figure 15. Global Urokinase Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Urokinase Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Urokinase Injection Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Urokinase Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Urokinase Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Urokinase Injection Sales Volume Share by Application (2021-2032) Figure 24. Global Urokinase Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Urokinase Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Urokinase Injection Sales Value Share by Application (2021-2032) Figure 27. Global Urokinase Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Urokinase Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Urokinase Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Urokinase Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Urokinase Injection Sales Value (2021-2032) & (US$ Million) Figure 32. North America Urokinase Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Urokinase Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Urokinase Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Urokinase Injection Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Urokinase Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Urokinase Injection Sales Value (2021-2032) & (US$ Million) Figure 38. South America Urokinase Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Urokinase Injection Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Urokinase Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Urokinase Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Urokinase Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Urokinase Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Urokinase Injection Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Urokinase Injection Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 10000-100000IU
  • 100000-1000000IU
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • NDPHARM
  • Microbic Biosystems Inc
  • Techpool
  • Jiangsu Aidea Pharmaceutical
  • Jiangxi Haoran Bio-Pharma
  • LIVZON
  • Wanhua Biochem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urokinase Injection Sales Value (2021-2032)
  4. 1.2.2 Global Urokinase Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Urokinase Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Urokinase Injection Market Dynamics
  1. 2.1 Urokinase Injection Industry Trends
  2. 2.2 Urokinase Injection Industry Drivers
  3. 2.3 Urokinase Injection Industry Opportunities and Challenges
  4. 2.4 Urokinase Injection Industry Restraints
3 Urokinase Injection Market by Company
  1. 3.1 Global Urokinase Injection Company Revenue Ranking in 2025
  2. 3.2 Global Urokinase Injection Revenue by Company (2021-2026)
  3. 3.3 Global Urokinase Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Urokinase Injection Average Price by Company (2021-2026)
  5. 3.5 Global Urokinase Injection Company Ranking (2024-2026)
  6. 3.6 Global Urokinase Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Urokinase Injection Company Product Type and Application
  8. 3.8 Global Urokinase Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Urokinase Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Urokinase Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Urokinase Injection Market by Type
  1. 4.1 Urokinase Injection Type Introduction
  2. 4.1.1 10000-100000IU
  3. 4.1.2 100000-1000000IU
  4. 4.1.3 Others
  5. 4.2 Global Urokinase Injection Sales Volume by Type
  6. 4.2.1 Global Urokinase Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Urokinase Injection Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Urokinase Injection Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Urokinase Injection Sales Value by Type
  10. 4.3.1 Global Urokinase Injection Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Urokinase Injection Sales Value by Type (2021-2032)
  12. 4.3.3 Global Urokinase Injection Sales Value Share by Type (2021-2032)
5 Urokinase Injection Market by Application
  1. 5.1 Urokinase Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Urokinase Injection Sales Volume by Application
  6. 5.2.1 Global Urokinase Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Urokinase Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Urokinase Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Urokinase Injection Sales Value by Application
  10. 5.3.1 Global Urokinase Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Urokinase Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Urokinase Injection Sales Value Share by Application (2021-2032)
6 Urokinase Injection Regional Sales and Value Analysis
  1. 6.1 Global Urokinase Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urokinase Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Urokinase Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Urokinase Injection Sales by Region (2027-2032)
  5. 6.3 Global Urokinase Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Urokinase Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Urokinase Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Urokinase Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Urokinase Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Urokinase Injection Sales Value (2021-2032)
  12. 6.6.2 North America Urokinase Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Urokinase Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Urokinase Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Urokinase Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Urokinase Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Urokinase Injection Sales Value (2021-2032)
  21. 6.9.2 South America Urokinase Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Urokinase Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Urokinase Injection Sales Value Share by Country, 2025 VS 2032
7 Urokinase Injection Country-level Sales and Value Analysis
  1. 7.1 Global Urokinase Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urokinase Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Urokinase Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Urokinase Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Urokinase Injection Sales by Country (2027-2032)
  6. 7.4 Global Urokinase Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Urokinase Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Urokinase Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Urokinase Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Urokinase Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Urokinase Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Urokinase Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Urokinase Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Urokinase Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Urokinase Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Urokinase Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Urokinase Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Urokinase Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Urokinase Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Urokinase Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Urokinase Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Urokinase Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Urokinase Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Urokinase Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Urokinase Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Urokinase Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Urokinase Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Urokinase Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Urokinase Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Urokinase Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Urokinase Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Urokinase Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Urokinase Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Urokinase Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Urokinase Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Urokinase Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Urokinase Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Urokinase Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Urokinase Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 NDPHARM
  2. 8.1.1 NDPHARM Company Information
  3. 8.1.2 NDPHARM Business Overview
  4. 8.1.3 NDPHARM Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 NDPHARM Urokinase Injection Product Portfolio
  6. 8.1.5 NDPHARM Recent Developments
  7. 8.2 Microbic Biosystems Inc
  8. 8.2.1 Microbic Biosystems Inc Company Information
  9. 8.2.2 Microbic Biosystems Inc Business Overview
  10. 8.2.3 Microbic Biosystems Inc Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Microbic Biosystems Inc Urokinase Injection Product Portfolio
  12. 8.2.5 Microbic Biosystems Inc Recent Developments
  13. 8.3 Techpool
  14. 8.3.1 Techpool Company Information
  15. 8.3.2 Techpool Business Overview
  16. 8.3.3 Techpool Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Techpool Urokinase Injection Product Portfolio
  18. 8.3.5 Techpool Recent Developments
  19. 8.4 Jiangsu Aidea Pharmaceutical
  20. 8.4.1 Jiangsu Aidea Pharmaceutical Company Information
  21. 8.4.2 Jiangsu Aidea Pharmaceutical Business Overview
  22. 8.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Aidea Pharmaceutical Urokinase Injection Product Portfolio
  24. 8.4.5 Jiangsu Aidea Pharmaceutical Recent Developments
  25. 8.5 Jiangxi Haoran Bio-Pharma
  26. 8.5.1 Jiangxi Haoran Bio-Pharma Company Information
  27. 8.5.2 Jiangxi Haoran Bio-Pharma Business Overview
  28. 8.5.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jiangxi Haoran Bio-Pharma Urokinase Injection Product Portfolio
  30. 8.5.5 Jiangxi Haoran Bio-Pharma Recent Developments
  31. 8.6 LIVZON
  32. 8.6.1 LIVZON Company Information
  33. 8.6.2 LIVZON Business Overview
  34. 8.6.3 LIVZON Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 LIVZON Urokinase Injection Product Portfolio
  36. 8.6.5 LIVZON Recent Developments
  37. 8.7 Wanhua Biochem
  38. 8.7.1 Wanhua Biochem Company Information
  39. 8.7.2 Wanhua Biochem Business Overview
  40. 8.7.3 Wanhua Biochem Urokinase Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Wanhua Biochem Urokinase Injection Product Portfolio
  42. 8.7.5 Wanhua Biochem Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urokinase Injection Value Chain Analysis
  2. 9.1.1 Urokinase Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urokinase Injection Sales Mode & Process
  6. 9.2 Urokinase Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urokinase Injection Distributors
  9. 9.2.3 Urokinase Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst